UK: Company Says Cannabis Medicine Works in Key Trials
Science – Reuters
Company Says Cannabis Medicine Works in Key Trials
LONDON (Reuters) – GW Pharmaceuticals Plc. said on Tuesday its cannabis-based medicine was effective in treating multiple sclerosis and other patients in four key trials, paving the way for a launch in Britain as early as next year.
GW, which cultivates some 40,000 cannabis plants a year at a secret location in the English countryside, will submit its product for regulatory approval with Britain’s Medicines Control Agency early next year.
Preliminary results of the Phase III clinical trials — the last stage of drug testing before approval — showed GW’s oral cannabis spray was significantly better than placebo in reducing nerve damage pain, spasticity and sleep disturbance.
Shares in GW had jumped 17.5 percent to 151 pence Monday after the company announced it planned to unveil the Phase III results on Nov. 5.
Humma.. nästan så att man får lust att tågluffa lite. 😯 😆